![]() ![]() Hypoxia is common in various types of solid cancers and is associated with a more aggressive phenotype ( Brahimi-Horn et al, 2007). In this regard, early biomarkers are urgently needed to allow better clinical management of patients with NSCLC. Despite major advances in surgical techniques and new strategies of neoadjuvant treatment, long-term survival is achieved in only 5–10% of NSCLC patients ( Stinchcombe and Socinski, 2009). Non-small cell lung cancer (NSCLC) comprises approximately 80% of lung cancers, and nearly 50% of patients with stage I NSCLC die within 10 years of diagnosis ( Travis et al, 2004 Ou et al, 2007). High expression of CAIX in tumour tissue is a predictor of worse survival, and a high CAIX plasma level is an independent prognostic biomarker in patients with NSCLC, in particular in early-stage I+II carcinomas. In addition, a high CAIX plasma level was an independent variable predicting poor OS ( P<0.001) in patients with NSCLC. Multivariate Cox analyses revealed that high CAIX tissue expression ( P=0.002) was a factor of poor prognosis in patients with resectable NSCLC. A high level of CAIX in the plasma of patients was associated with shorter OS ( P<0.001) and DSS ( P<0.001), mostly in early stage I+II NSCLC. The CAIX plasma level was significantly higher in patients with NSCLC than in healthy individuals ( P<0.001). Results:ĬAIX tissue overexpression correlated with shorter overall survival (OS) ( P=0.05) and disease-specific survival (DSS) of patients ( P=0.002). The CAIX tissue immunostaining and plasma levels were correlated with clinicopathological factors and patient outcome. The plasma level of CAIX was determined by ELISA in 209 of these NSCLC patients and in 58 healthy individuals. Tissue microarrays containing 555 NSCLC tissue samples were generated for quantification of CAIX expression. This study was conducted to assess if the expression of CAIX in tumour tissue and/or plasma can be a prognostic factor in patients with non-small cell lung cancer (NSCLC). ![]() ![]() Carbonic anhydrase IX (CAIX) is an enzyme upregulated by hypoxia during tumour development and progression. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |